Inflammation and thrombosis in essential thrombocythemia and polycythemia vera different role of C-reactive protein and pentraxin 3

Haematologica

Volumn 96, Issue 2, 2011, Pages 315-318

  Barbui, Tiziano ^a   Carobbio, Alessandra ^a   Finazzi, Guido ^a   Vannucchi, Alessandro M ^b   Barosi, Giovanni ^c   Antonioli, Elisabetta ^b   Guglielmelli, Paola ^b   Pancrazzi, Alessandro ^b   Salmoiraghi, Silvia ^a   Zilio, Pio ^d   Ottomano, Cosimo ^d   Marchioli, Roberto ^e   Cuccovillo, Ivan ^f   Bottazzi, Barbara ^f   Mantovani, Alberto ^f   Rambaldi, Alessandro ^a  

^a OSPEDALI RIUNITI   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d Ospedali Riuniti di Bergamo   (Taiwan)

^e Laboratory of Clinical Epidemiology of Cardiovascular Disease   (Taiwan)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

C reactive protein; Essential thrombocythemia; Pentraxin 3; Polycythemia vera

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; HYDROXYUREA; JANUS KINASE 2; PENTRAXIN 3;

ACUTE HEART INFARCTION; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; EFFECT SIZE; FEMALE; GENE MUTATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOTYPE; PHLEBOTOMY; POLYCYTHEMIA VERA; PREVALENCE; PROTEIN FUNCTION; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STROKE; THROMBOCYTHEMIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM;

EID: 79551644817     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.031070     Document Type: Article

References (19)

1. Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008;112(8): 3135-7.
2. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224-32.
3. Mukamal KJ, Wellenius GA, Mittleman MA. Hematologic parameters, atherosclerotic progression, and prognosis in patients with previous coronary artery bypass grafting (from the Post CABG Trial). Am J Cardiol. 2009;103(3):328-32.
4. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159-66.
5. Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol. 2008;26(1)6:2732-6.
6. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009;114(4):759-63.
7. Kralovics R, Teo SS, Buser AS, Brutsche M, Tiedt R, Tichelli A, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005;106(10):3374-6.
8. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132-40.
9. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110(16):2349-54.
10. Salio M, Chimenti S, De Angelis N, Molla F, Maina V, Nebuloni M, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2008;117(8):1055-64.
11. Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol. 2005;130(5):709-15.
12. Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia. 2006;20(6):1055-60.
13. Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med. 2009;47(4):471-7.
14. Quist-Paulsen P, Naess IA, Cannegieter SC, Romundstad PR, Christiansen SC, Rosendaal FR, et al. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica. 2010;95(1): 119-25.
15. Boekholdt SM, Kastelein JJ. C-reactive protein and cardiovascular risk: more fuel to the fire. Lancet. 2010;375(9709):95-6.
16. Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009;120(8):699-708.
17. Deban L, Russo RC, Sironi M, Moalli F, Scanziani M, Zambelli V, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol. 2010;11(4):328- 34.
18. Ley K. The role of selectins in inflammation and disease. Trends Mol Med. 2003;9(6): 263-8.
19. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006;116(12):3211-9.